Welcome to our dedicated page for Kronos Bio news (Ticker: KRON), a resource for investors and traders seeking the latest updates and insights on Kronos Bio stock.
Kronos Bio Inc. news covers the company's historical work as a biopharmaceutical developer of small molecule therapeutics targeting deregulated transcription in cancer and autoimmune disease. Recurring updates include financial results, strategic-alternative reviews, governance changes, expense reductions, and pipeline decisions involving istisociclib and p300 lysine acetyltransferase inhibitor programs.
Company announcements also describe preclinical research for KB-9558 in multiple myeloma and HPV-driven tumors and KB-7898 in autoimmune indications such as Sjögren's disease. Later corporate updates center on material agreements, shareholder matters, capital-structure disclosure, and public-company status changes following the strategic-review process.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Kronos Bio, Inc. (Nasdaq: KRON) announced the appointment of Dr. Roger Dansey to its Board of Directors on April 24, 2023. Dr. Dansey, an expert in oncology drug development, currently serves as the president of research and development at Seagen Inc. His extensive experience includes senior leadership roles at Merck, Gilead Sciences, and Amgen. CEO Norbert Bischofberger welcomed Dr. Dansey, emphasizing his deep understanding of the clinical research landscape, which will significantly aid Kronos in advancing its product portfolio targeting dysregulated transcription. The company is pursuing two investigational compounds, KB-0742 for MYC-amplified tumors and lanraplenib for FLT3-mutated acute myeloid leukemia, highlighting its focus on innovative cancer therapies.
Kronos Bio, Inc. (Nasdaq: KRON) announced the appointment of Katherine Vega Stultz to its Board of Directors, effective April 11, 2023, following the departure of Otello Stampacchia, Ph.D. on March 31, 2023. Stultz brings over 25 years of biopharmaceutical experience, currently serving as CEO of Ocelot Bio and previously holding significant roles at Graphite Bio and Celgene. CEO Norbert Bischofberger expressed confidence that Stultz's expertise in oncology drug development will enhance Kronos' clinical pipeline efforts. Kronos Bio focuses on developing therapies for challenging cancers, including investigational compounds like the CDK9 inhibitor KB-0742 and lanraplenib for acute myeloid leukemia.